Snapshot

Genomics & sequencing companies sell the hardware and chemistry that read DNA and RNA — the raw biological data underlying drug discovery, cancer diagnostics, prenatal screening, and population health. The dominant product is the next-generation sequencer (NGS — a machine that reads millions of DNA fragments in parallel). The business model is razor-and-blade: sell an instrument at modest margin, then earn recurring revenue on flow cells and reagent kits consumed with every sequencing run. Illumina controls roughly 80% of the NGS market by revenue est.. The NGS market was valued at ~$10.4B in 2025, growing at ~16% CAGR toward ~$38B by 2034 est.. Long-read sequencing (a newer technology reading longer DNA fragments, important for structural variants) is a smaller but faster-growing sub-market: ~$758M in 2024, forecast at ~$3.1B by 2029 (~33% CAGR) est.. The four companies here range from a $24.6B market cap dominant platform (ILMN) to a $14M micro-cap (BNGO).

The group's combined revenue is ~$4.8B/yr (dominated by Illumina's $4.3B). ~74% of Illumina's revenue is consumables — recurring, high-margin blades attached to an installed base of ~890 NovaSeq X units and thousands of older sequencers. That consumable stream grew 2% in FY2025; sequencing volume rose 30%+ YoY on connected instruments. Every new clinical application (cancer profiling, prenatal, pharmacogenomics) and every AI model trained on genomic data creates demand for more runs on existing instruments.

The product & how money is made

The core product is a DNA/RNA sequencing system — a benchtop or floor-standing instrument that reads the order of nucleotide bases (A, T, C, G) in biological samples. The output is raw sequence data, measured in gigabases (Gb — billions of bases read). One whole human genome is ~3.1 billion bases (~90–100 Gb of raw data at standard 30× coverage).

Three distinct technology tiers, each with different economics:

• Short-read sequencing (Illumina) — reads DNA in fragments of ~150–300 bases. Uses sequencing-by-synthesis (SBS) chemistry: fluorescently labeled nucleotides are incorporated one at a time and photographed. The consumable is a flow cell plus reagent cartridge, consumed with every run. NovaSeq X reagent cost per whole human genome: ~$200. Instrument list price: ~$985K (NovaSeq X) to ~$1.25M (NovaSeq X Plus).
• Long-read sequencing (PacBio) — reads fragments of 10,000–100,000+ bases using SMRT (Single-Molecule Real-Time) technology. Essential for detecting structural variants, phasing, and epigenetic modifications. The consumable is a SMRT Cell. Revio lists at ~$779K; Vega at ~$179K.
• Single-cell and spatial genomics (10x Genomics) — does not sequence DNA itself but prepares samples so that each individual cell's contents can be tagged and then read on an Illumina sequencer. The Chromium system partitions cells into nanoliter droplets; the Visium/Xenium spatial platforms map gene activity to physical locations in a tissue slice. Consumables are library-prep kits and spatial slides, consumed upstream of sequencing.

Bionano (BNGO) is not a sequencer — its Saphyr system performs optical genome mapping (OGM), which images very long DNA molecules (~300 kb) to detect large structural variants. It is complementary to, not competitive with, sequencing. Revenue is $28.5M/yr with a $14M market cap and ~$21M in cash (partially restricted) as of late 2024.

How money flows:

• Cash in (instruments): one-time sale or lease of the hardware. Illumina instrument revenue: ~$1.1B in FY2025 (down 4%). PacBio: $53.8M. TXG: $56.8M — both declining.
• Cash in (consumables): recurring purchases every time a sample is run. Illumina: ~$3.2B (74% of revenue, up 2%). PacBio: $82M (51% of revenue, up 17%). TXG: $507M (79% of revenue, up 3%).
• Cash out: R&D (Illumina ~$950M/yr; PacBio and TXG each ~$150–200M); manufacturing; sales force covering thousands of research labs and hospitals. Illumina is the only company in this group generating positive free cash flow ($931M in FY2025).

Sources: Illumina FY2025 10-K, PacBio FY2025 earnings release, TXG FY2025 earnings release, BNGO FY2024 earnings release.

Demand

Contracted / observable demand

• Illumina backlog: $738M as of FY2025, with 13% expected to ship beyond 2026. contracted
• Sequencing volume on connected instruments: grew >30% YoY through 2025 (observable through Illumina's telemetry). contracted
• NovaSeq X transition: 55% of Illumina revenue on X platform by Q4 2025; ~90% of research volumes converted, ~67% of clinical. Remaining legacy NovaSeq 6000 customers expected to migrate by end of 2026, pulling through instrument purchases. contracted
• PacBio Revio pull-through: ~$233K annualized consumables per Revio system in FY2025. With 346 cumulative Revio shipments by Q1 2026, that implies ~$80M/yr of consumable demand from the installed base. contracted
• Bionano OGM publications: 336 in 2024, up 19% YoY. CPT code for OGM effective January 1, 2025, enabling reimbursement for the first time. contracted

Forecast demand

• Clinical genomics expansion: oncology (tumor profiling), NIPT, pharmacogenomics, rare disease diagnosis, and liquid biopsy all represent growing clinical mandates. Clinical sequencing is converting from optional to standard-of-care in oncology — the clinical segment is projected to be 52% of NGS revenue by 2026. est.
• Population-scale programs: government genome projects (UK Biobank, Genome India, All of Us at 1M+ participants) create multi-year sequencing contracts measured in hundreds of thousands of whole genomes. est.
• AI/AGI multiplier: every AI model trained on biological data (protein structure prediction, drug target identification, polygenic risk scoring) needs more genomic data. As AI interpretation of genomes improves, the value of each additional genome sequenced rises, creating a positive feedback loop between AI capability and sequencing demand. est.
• Long-read sequencing: forecast to grow from $758M (2024) to ~$3.1B (2029) at ~33% CAGR as structural variant detection moves from research into clinical diagnostics. est.
• Spatial biology: TXG's spatial transcriptomics market is early-stage. TAM estimated at $7–10B long-term but currently <$1B. est.

Sources: Fortune Business Insights NGS market report; MarketsandMarkets long-read sequencing report; Illumina/PacBio/TXG earnings releases and calls.

Supply

Capacity & installed base

• Illumina: 890 NovaSeq X systems installed (end Q4 2025), expected to reach ~1,090–1,130 by end of 2026 (guidance: 200–240 placements/yr). Each NovaSeq X Plus can process ~20,000 whole genomes per year est.. Total Illumina sequencer fleet across all platforms numbers in the thousands — instruments in >10,000 labs in 140+ countries.
• PacBio: 346 Revio and 174 Vega systems shipped cumulatively through Q1 2026 (520 current-gen instruments total). SPRQ-Nx chemistry upgrade (launched May 2026) allows each SMRT Cell to be used 3 times, tripling consumable yield per dollar for customers while improving PacBio's gross margin.
• 10x Genomics: does not disclose installed base. Revenue implies thousands of Chromium controllers in the field (instruments cost ~$30–75K, vs. consumables at ~$507M/yr) est.. Xenium spatial analyzer launched in 2023; spatial instruments revenue grew from ~$34M.
• Bionano: 371 Saphyr OGM systems installed (end 2024), with 15–20 additional planned for 2025.

Bottlenecks

• Academic funding cycles: the primary constraint on demand growth is not manufacturing capacity but lab budgets. NIH funding, university grant cycles, and pharma R&D budgets gate how many sequencing runs labs can afford. Illumina's FY2025 instrument revenue fell 4% as labs deferred capex.
• Manufacturing is not the bottleneck: unlike GPUs or data center power, sequencer manufacturers can produce instruments faster than labs buy them. The limiting factor is customer willingness to spend capital.
• Regulatory approval: each new clinical use of sequencing requires FDA clearance or CLIA lab validation (1–3 years). This gates clinical demand expansion.
• Reimbursement: payers must cover the cost of clinical sequencing tests for hospitals to order them. Reimbursement decisions lag clinical evidence by years. Bionano's CPT code for OGM (effective Jan 2025) took years after the technology was available.

Sources: Illumina Q4 2025 earnings call (890 NovaSeq X, 200–240/yr guidance); PacBio Q1 2026 earnings call (346 Revio, 174 Vega); BNGO FY2024 earnings (371 Saphyr).

The gap

The genomics instrument market is demand-constrained, not supply-constrained. Manufacturers have production capacity to build more instruments than labs are buying. The bottleneck is on the customer side: funding, budget approval, and clinical adoption timelines.

Pricing direction: Sequencing costs continue to fall (~3× drop from NovaSeq 6000 to NovaSeq X per genome). Historically, each cost drop has increased volume more than proportionally — the "$1,000 genome" unlocked clinical adoption, the "$200 genome" is unlocking population-scale screening. Illumina's FY2025 was flat; guidance for FY2026 is 4–6% growth ($4.52–$4.62B). PacBio's SPRQ-Nx chemistry simultaneously lowers customer cost (3× SMRT Cell reuse) and improves PacBio's own margins.

Sources: Illumina FY2025 and Q1 2026 earnings releases; PacBio FY2025 and Q1 2026 earnings releases; TXG FY2025 and Q1 2026 earnings releases.

The players

Sources: Illumina FY2025 and Q1 2026 earnings releases; PacBio FY2025 and Q1 2026 earnings releases; TXG FY2025 and Q1 2026 earnings releases; BNGO FY2024 earnings release and StockAnalysis.com.

Not listed but relevant: Oxford Nanopore Technologies (ONT, London-listed) is PacBio's primary competitor in long-read sequencing, using nanopore technology. Not US-listed so excluded from the ticker list but holds meaningful long-read market share. Twist Bioscience (TWST) makes synthetic DNA (writing DNA, not reading it) — a different product.

The price of exposure

• Illumina (ILMN) — $24.6B market cap for $4.34B revenue, $931M FCF. ~5.7× revenue and ~26× free cash flow. Net debt ~$370M ($2.0B debt minus $1.6B cash). FY2026 guidance: $4.52–$4.62B revenue (4–6% growth). $1.5B buyback authorized. Stock at $162.55 (52-week range: $79–$166). Down from all-time highs above $500 in 2021.
• PacBio (PACB) — $491M market cap for $160M revenue. ~3.1× revenue, no earnings or FCF. Burned ~$159M (non-GAAP net loss) in FY2025 with $280M in cash. Cash runway roughly 1.5–2 years before needing capital est.. SPRQ-Nx (launched May 2026) is a potential consumable-growth and margin-expansion catalyst. Stock at $1.58 (52-week range: $0.96–$2.73).
• 10x Genomics (TXG) — $3.9B market cap for $643M revenue. ~6.1× revenue, net loss narrowing (-$43.5M in FY2025). $523M cash, minimal debt. Spatial biology consumables growing 30%+. Stock at $30.71 (52-week range: $8.95–$31.15).
• Bionano (BNGO) — $14M market cap for $28.5M revenue. Below 0.5× revenue. ~$21M in cash (partially restricted), convertible debt outstanding, $400M shelf filing, CEO departed, 97 employees. Revenue declined 7% in FY2024; FY2026 guide $30–33M.

Sources: StockAnalysis.com for current prices/caps (Jun 2, 2026); company earnings releases for revenue/FCF/cash.

What to deep-dive next

• Illumina (ILMN): Does the NovaSeq X consumable ramp (55% revenue transitioned, 30%+ volume growth) translate into sustained revenue growth, or do China headwinds (6% of revenue, under export restrictions) and capex deferrals keep the top line flat? SomaLogic acquisition (proteomics) is 24–36 months from meaningful revenue contribution est.. Read the 10-K for consumables-vs-instruments breakdown, geographic risk, and $738M backlog composition.
• PacBio (PACB): SPRQ-Nx launched commercially — track Revio placements and consumable pull-through in Q2/Q3 2026 for evidence of inflection vs. continued cash burn. Can PacBio reach cash-flow breakeven before needing to raise capital? If consumable revenue grows to ~$100M+ and non-GAAP gross margins hold at 40%, the path is arithmetically plausible est..
• 10x Genomics (TXG): Spatial biology is the growth lever. Track Xenium instrument placements and spatial consumable revenue as percentage of total. Spatial consumables sustained 30%+ growth through Q1 2026.
• Bionano (BNGO): Two questions: (a) does the CPT code drive meaningful reimbursement-based OGM adoption, and (b) can the company survive on current cash or raise capital without catastrophic dilution? At $14M market cap with dwindling cash, this is a distressed balance sheet.

Sources & confidence

• Hard (from filings): All company financials (revenue, margins, net income, FCF, cash positions, instrument placements, consumable revenue splits, guidance) are from FY2025 earnings releases and Q1 2026 earnings releases/calls filed with the SEC. Illumina NovaSeq X installed base (890, Q4 2025) from Q4 2025 earnings call transcript. PacBio cumulative shipments (346 Revio, 174 Vega) from Q1 2026 earnings call. Bionano 371 Saphyr installed base and CPT code from FY2024 earnings release. Stock prices and market caps from StockAnalysis.com, Jun 2, 2026.
• Market research (directional): NGS market size ($10.4B in 2025, ~16% CAGR) from Fortune Business Insights. Long-read sequencing market ($758M in 2024, ~33% CAGR) from MarketsandMarkets. DNA sequencing market ($14.7B in 2025) from Precedence Research. Third-party estimates with varying methodologies — treat as order-of-magnitude figures. est.
• Illumina ~80% market share: widely cited by analysts and in company presentations but not a precise SEC-filed number. est.
• Sequencing cost ($200/genome): Illumina's published list price on the NovaSeq X 25B flow cell. Actual customer costs vary with volume, institutional pricing, and labor.
• Grounding source: 500-stocks sector scan #9 (Healthcare, Biotech & Life Sciences), "Genomics & Sequencing" sub-section. File: /Users/ravf/projects/work/.claude/worktrees/sector-b2/research/investments/500-stocks/09-healthcare-biotech.html

Forecasts (AI/AGI demand multiplier, spatial biology TAM) are explicitly labeled in the Demand section.